Michael J. Grant MD
Assistant Professor of Medicine, Yale Cancer Center, New Haven, ConnecticutMichael Grant, MD, is an Assistant Professor of Medicine (Medical Oncology). Dr. Grant received his medical degree from the Albert Einstein School of Medicine and did his residency in Internal Medicine at Duke University School of Medicine. He completed his fellowship at Yale School of Medicine during which he was enrolled in the Yale Cancer Center T32 Advanced Training Program (YCC-ATPP) for Physician-Scientists. The YCC-ATPP provides funding to fellows who are strongly committed to being independent physician-scientists performing basic, translational, clinical, or outcomes research in a cancer-related field.
Dr. Grant cares for patients with thoracic and genitourinary malignancies and his current research interests include targeted and immunotherapy approaches to the treatment of non-small cell lung cancer. In 2021, he received the ASCO Conquer Cancer Young Investigator Award to study sensitivity and resistance to EGFR-targeted therapies in patients with NSCLC harboring certain EGFR mutations.
Recent Contributions to PracticeUpdate:
- Overall Survival Outcomes of Patients With Advanced EGFR-Mutant NSCLC Receiving Osimertinib vs Gefitinib Followed by Osimertinib
- Advice and Importance of Patient Cases for Clinicians
- The Value of Patient Cases
- Staying Updated on Medical Literature and the Associated Challenges
- Resected Non-Small Cell Lung Cancer: How Far to Go With Molecular Testing?
- 5 Tips for Staying Updated in Medical Literature
- Navigating the New Neoadjuvant Paradigm in Resectable NSCLC
- EGFR Exon 20 Insertions: Welcoming the New Treatment Paradigm
- Resectable Lung Adenocarcinoma — Yes to Immunotherapy, but When?
- Acquired Resistance to Osimertinib in EGFR Mutant NSCLC